VC Lightstone has $250 million in the bank for life science research.

Iontas will use its phage display libraries and other antibody discovery capabilities to provide Glythera with a key component of its planned ADCs.

XW Laboratories has seen a $17.5 million series B, bumping up its total raise from its first round to $23 million.

Eric Carlson, Ph.D., has become the latest in a string of former Alcon employees to land at the smaller eye disease specialist.

The former GSK CEO is taking up a venture partner post at the VC shop, setting him up to offer advice on the positioning of its portfolio companies.

Disarm Therapeutics has seen a strong $30 million series A round as it looks for a breakthrough approach in axonal degeneration.

Venture capital group Flagship Pioneering filed a $500 million offering with the Securities & Exchange Commission to set up a sixth investment fund.

Ultragenyx is putting up $138 million in cash to wrestle gene therapy biotech Dimension away from its first suitor.